Novel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Dai, Lin ^a   Wang, Luying ^a   Deng, Lihong ^a   Liu, Jing ^a   Lei, Jiandu ^a   Li, Dan ^a   He, Jing ^a  

^a BEIJING FORESTRY UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; MACROGOL DERIVATIVE;

ANIMAL; C57BL MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; LUNG NEOPLASMS; MORTALITY; MOUSE; PATHOLOGY; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SURVIVAL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905176479     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05871     Document Type: Article

References (47)

1. Zhong, H. et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 13, 5455-5462 (2007).
2. Haick, H., Broza, Y. Y., Mochalski, P., Ruzsanyi, V. & Amann, A. Assessment, origin, and implementation of breath volatile cancer markers. Chem. Soc. Rev. 43, 1423-1449 (2014).
3. McGuire, M. J. et al. Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. Sci. Rep. 4, 4480; doi:10.1038/ srep04480 (2014).
4. Dela Cruz, C. S., Tanoue, L. T. & Matthay, R. A. Lung cancer: epidemiology, etiology, and prevention. Clin. Chest Med. 32, 605-644 (2011).
5. Meshnick, S. R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32, 1655-1660 (2002).
6. O'Neill, P. M. & Posner, G. H. A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 47, 2945-2964 (2004).
7. Hien, T. T. & White, N. J. Qinghaosu. Lancet 341, 603-608 (1993).
8. Klayman, D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 1049-1055 (1985).
9. Zhang, C. Z., Zhang, H., Yun, J., Chen, G. G. & Lai, P. B. S. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem. Pharmacol. 83, 1278-1289 (2012).
10. Wang, S. J. et al. Dihydroartemisinin inactivates NF-kB and potentiates the antitumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett. 293, 99-108 (2010).
11. Paeshuyse, J. et al. Hemin potentiates the antihepatitis C virus activity of the antimalarial drug artemisinin. Biochem. Biophys. Res. Commun. 348, 139-144 (2006).
12. Wu, G. S. et al. Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacol. Rep. 65, 453-459 (2013).
13. Lu, J. J. et al.Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYCoverexpressing tumor cells. Biochem. Pharmacol. 80, 22-30 (2010).
14. Dhingra, V., Rao, K. V. & Narasu, M. L. Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci. 66, 279-300 (1999).
15. Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H. & Chitambar, C. R. The antimalarial artesunate is also active against cancer. Int. J. Oncol. 18, 767-773 (2001).
16. Nam, W. et al. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck. 29, 335-340 (2007).
17. Galal, A. M. et al. Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. Bioorg. Med. Chem. 17, 741-751 (2009).
18. Bora, P. P., Baruah, N., Bez, G. & Barua, N. C. New method for the synthesis of ether derivatives of artemisinin. Synthetic. Commun. 42, 1218-1225 (2012).
19. Li, W., Zhan, P., De Clercq, E., Lou, H. & Liu, X. Current drug research on PEGylation with small molecular agents. Prog. Polym. Sci. 38, 421-444 (2013).
20. Kang, J. S., DeLuca, P. P. & Lee, K. C. Emerging PEGylated drugs. Expert Opin. Emerging Drugs. 14, 363-380 (2009).
21. Duncan, R. Polymer therapeutics as nanomedicines: new perspectives. Curr. Opin. Biotechnol. 22, 492-501 (2011).
22. Veronese, F. M. & Pasut, G. PEGylation, successful approach to drug delivery. Drug Discovery Today. 10, 1451-1458 (2005).
23. Eto, Y., Yoshioka, Y., Mukai, Y., Okada, N. & Nakagawa, S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm. 354, 3-8 (2008).
24. Wang, Y. S., Youngster, S., Grace, M., Bausch, J., Bordens, R. & Wyss, D. F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Delivery Rev. 54, 547-570 (2002).
25. Greenwald, R. B., Choe, Y. H.,McGuire, J. & Conover, C. D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Delivery Rev. 55, 217-250 (2003).
26. Fee, C. J. & Van Alstine, J. M. PEG-proteins: reaction engineering and separation issues. Chem. Eng. Sci. 61, 924-924 (2005).
27. Martino, R., Malet-Martino, M., Gilard, V. & Balayssac, S. Counterfeit drugs: analytical techniques for their identification. Anal. Bioanal. Chem. 398, 77-92 (2010).
28. Choi, K. Y. et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials. 32, 1880-1889 (2011).
29. Chiang, W. H. et al. Functionalized polymersomes with outlayered polyelectrolyte gels for potential tumor-targeted delivery of multimodal therapies and MR imaging. J. Controlled Release. 168, 280-288 (2013).
30. Xiao, W. Z., Zhan, L. Z., Zhang, M. Y. & Lin, Y. F. Determination of dihydroartemisinin of compound dihydroartemisinin tablets by tri-wavelength spectrophotosmetry. J. Pharm. Pract. 21, 92-94 (2003).
31. National Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China. Part 2. Beijing: Chemical Industry Press. Appendix, 181-182 (2010).
32. Pendri, A., Gilbert, C. W., Soundararajan, S., Bolikal, D., Shorr, R. G. L. & Greenwald, R. B. PEG modified anticancer drugs: Synthesis and biological activity. J. Bioact. Compat. Polym. 11, 122-135 (1996).
33. van Sluis, R. et al. In vivo imaging of extracellular pH using 1H MRSI. Magn. Reson. Med. 41, 743-750 (1999).
34. Cardone, R. A., Casavola, V. & Reshkin, S. J. The role of disturbed pH dynamics and the Na1/H1 exchanger in metastasis. Nat. Rev. Cancer. 5, 786-795 (2005).
35. Reul, R., Nguyen, J. & Kissel, T. Amine-modified hyperbranched polyesters as non-toxic, biodegradable gene delivery systems. Biomaterials. 30, 5815-5824 (2009).
36. Gu,H.M., Warhurst,D. C. & Peters, W. Hemolysis induced by artemisinin and its derivatives in vitro. Acta Pharmacol. Sin. 7, 269-272 (1986).
37. Zhang, Y. et al. Cytotoxicity effects of graphene and single-wall carbon nanotubes in neural phaeochromocytomaderived PC12 cells. Acs Nano. 4, 3181-3186 (2010).
38. Ge, C. et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 108, 16968-16973 (2011).
39. Fang, J., Nakamura, H. & Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Delivery Rev. 63, 136-151 (2011).
40. Saari, W. S., Schwering, J. E., Lyle, P. A., Smith, S. J. & Engelhardt, E. L. Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole. J. Med. Chem. 33, 97-101 (1990).
41. Jäger, S., Winkler, K., Pfüller, U. & Scheffler, A. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta. medica. 73, 157-162 (2007).
42. Nguyen, J., Steele, T. W. J., Merkel, O., Reul, R. & Kissel, T. Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J. Controlled Release. 132, 243-51 (2008).
43. Reul, R., Nguyen, J. & Kissel, T. Amine-modified hyperbranched polyesters as non-toxic, biodegradable gene delivery systems. Biomaterials. 30, 5815-5824 (2009).
44. Yue, H. et al. The role of the lateral dimension of graphene oxide in the regulation of cellular responses. Biomaterials. 33, 4013-4021 (2012).
45. Wei, W. et al. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials. 34, 3912-3923 (2013).
46. Unger, F., Wittmar, M. & Kissel, T. Branched polyesters based on poly[vinyl-3- (dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly- (D,L-lactide-co-glycolide): effects of polymer structure on cytotoxicity. Biomaterials. 28, 1610-1619 (2007).
47. Shi, B., Fang, C. & Pei, Y. Y. Stealth PEG-PHDCAniosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J. Pharm. Sci. 95, 1873-1887(2006).